Risk stratification in PAH: are any of our patients really "low risk"?

28 August 2017 (12:50 - 13:00)

Organised by:

About the speaker

Professor Irene Marthe Lang

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail

Introduction - Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy.

Professor I. Lang (Vienna, AT)

Presentation thumbnail

The importance of reducing hospitalisations in PAH.

Professor J. Vachiery (Brussels, BE)

Presentation thumbnail

Can your connective tissue disease-associated PAH patients achieve similar outcomes to your idiopathic PAH patients?

Doctor J. Coghlan (London, GB)

Presentation thumbnail

Q&A - Can you achieve more for your PAH patients? An expert review of key recent data with initial combination therapy.

Professor I. Lang (Vienna, AT)

Access the full session

Session thumbnail

Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy

The Event

ESC Congress 2017

28 August 2017 12:50 CET

You may be interested in

Congress Session

Breaking the pressure: innovations in pulmonary hypertension management

18 May 2025

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

15 April 2024

Congress Session

Gaps in risk stratification for patients with structural heart disease

31 March 2025

Congress Presentation

Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)

3 September 2019

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources